BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Crizotinib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Crizotinib\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04322890-1966@assetmemo.bio
DTSTAMP:20261121T004015Z
DTSTART;VALUE=DATE:20261224
DTEND;VALUE=DATE:20261225
SUMMARY:Crizotinib: Phase 2 readout est. (NCT04322890)
DESCRIPTION:Crizotinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Trea
 tment Strategies and Survival Outcome for Non-small Cell Lung Cancer With 
 Oncogenic Mutation\nEstimated primary completion: 24 December 2026. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/crizotinib#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT04322890
URL:https://assetmemo.bio/drug/crizotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03297606-1966@assetmemo.bio
DTSTAMP:20261121T004015Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Crizotinib: Phase 2 readout est. (NCT03297606)
DESCRIPTION:Crizotinib\, phase 2.\nStudy: Canadian Profiling and Targeted A
 gent Utilization Trial (CAPTUR)\nEstimated primary completion: 31 December
  2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/crizotinib#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0329760
 6
URL:https://assetmemo.bio/drug/crizotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05987332-1966@assetmemo.bio
DTSTAMP:20261121T004015Z
DTSTART;VALUE=DATE:20270115
DTEND;VALUE=DATE:20270116
SUMMARY:Crizotinib: Phase 2/3 readout est. (NCT05987332)
DESCRIPTION:Crizotinib\, phase 2/3.\nStudy: IDE196 (Darovasertib) in Combin
 ation With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma\n
 Estimated primary completion: 15 January 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/crizotinib#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT05987332
URL:https://assetmemo.bio/drug/crizotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03947385-1966@assetmemo.bio
DTSTAMP:20261121T004015Z
DTSTART;VALUE=DATE:20270129
DTEND;VALUE=DATE:20270130
SUMMARY:Crizotinib: Phase 1/2 readout est. (NCT03947385)
DESCRIPTION:Crizotinib\, phase 1/2.\nStudy: Study of IDE196 in Patients Wit
 h Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions\nEstimated prim
 ary completion: 29 January 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/crizotinib#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT03947385
URL:https://assetmemo.bio/drug/crizotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02925234-1966@assetmemo.bio
DTSTAMP:20261121T004015Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Crizotinib: Phase 2 readout est. (NCT02925234)
DESCRIPTION:Crizotinib\, phase 2.\nStudy: The Drug Rediscovery Protocol (DR
 UP Trial)\nEstimated primary completion: September 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/crizotinib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT02925234
URL:https://assetmemo.bio/drug/crizotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06563999-1966@assetmemo.bio
DTSTAMP:20261121T004015Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Crizotinib: Phase 2 readout est. (NCT06563999)
DESCRIPTION:Crizotinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Neoa
 djuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harb
 oring Rare Mutations.\nEstimated primary completion: 1 November 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/crizotinib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06563999
URL:https://assetmemo.bio/drug/crizotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04693468-1966@assetmemo.bio
DTSTAMP:20261121T004015Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Crizotinib: Phase 1 readout est. (NCT04693468)
DESCRIPTION:Crizotinib\, phase 1.\nStudy: Talazoparib and Palbociclib\, Axi
 tinib\, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tu
 mors\, TalaCom Trial\nEstimated primary completion: 31 December 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/crizotinib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT04693468
URL:https://assetmemo.bio/drug/crizotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02465060-1966@assetmemo.bio
DTSTAMP:20261121T004015Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Crizotinib: Phase 2 readout est. (NCT02465060)
DESCRIPTION:Crizotinib\, phase 2.\nStudy: Targeted Therapy Directed by Gene
 tic Testing in Treating Patients With Advanced Refractory Solid Tumors\, L
 ymphomas\, or Multiple Myeloma (The MATCH Screening Trial)\nEstimated prim
 ary completion: 31 December 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/crizotinib#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT02465060
URL:https://assetmemo.bio/drug/crizotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05160922-1966@assetmemo.bio
DTSTAMP:20261121T004015Z
DTSTART;VALUE=DATE:20280321
DTEND;VALUE=DATE:20280322
SUMMARY:Crizotinib: Phase 4 readout est. (NCT05160922)
DESCRIPTION:Crizotinib\, phase 4\, Non-Small Cell Lung Cancer.\nStudy: Criz
 otinib Continuation Clinical Study\nEstimated primary completion: 21 March
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/crizotinib#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0516092
 2
URL:https://assetmemo.bio/drug/crizotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07804186-1966@assetmemo.bio
DTSTAMP:20261121T004015Z
DTSTART;VALUE=DATE:20340331
DTEND;VALUE=DATE:20340401
SUMMARY:Crizotinib: Phase 3 readout est. (NCT07804186)
DESCRIPTION:Crizotinib\, phase 3.\nStudy: Study of Adjuvant Darovasertib an
 d Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma\nE
 stimated primary completion: March 2034. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/crizotinib#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07804186
URL:https://assetmemo.bio/drug/crizotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02201992-1966@assetmemo.bio
DTSTAMP:20261121T004015Z
DTSTART;VALUE=DATE:20360501
DTEND;VALUE=DATE:20360502
SUMMARY:Crizotinib: Phase 3 readout est. (NCT02201992)
DESCRIPTION:Crizotinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Criz
 otinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer 
 That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Tr
 eatment Trial)\nEstimated primary completion: 1 May 2036. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/crizotinib#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT02201992
URL:https://assetmemo.bio/drug/crizotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05725200-1966@assetmemo.bio
DTSTAMP:20261121T004015Z
DTSTART;VALUE=DATE:20381231
DTEND;VALUE=DATE:20390101
SUMMARY:Crizotinib: Phase 2 readout est. (NCT05725200)
DESCRIPTION:Crizotinib\, phase 2.\nStudy: Study to Investigate Outcome of I
 ndividualized Treatment in Patients With Metastatic Colorectal Cancer\nEst
 imated primary completion: 31 December 2038. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/crizotinib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT05725200
URL:https://assetmemo.bio/drug/crizotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
